Literature DB >> 22941118

Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.

Guler Yavas1, Cagdas Yavas, Hilal Acar, Hatice Toy, Deniz Yuce, Ozlem Ata.   

Abstract

PURPOSE: The purpose of this study is to compare the effects of anastrozole, letrozole and tamoxifen on radiation-induced pulmonary fibrosis.
METHODS: Eighty female Wistar albino rats were divided into eight groups. Group (G) 1 was defined as control group. G2 was radiation therapy (RT) only group. Groups 3, 4 and 5 were tamoxifen, anastrozole and letrozole control groups respectively. Groups 6, 7 and 8 were RT plus tamoxifen, anastrozole and letrozole groups, respectively. A single dose of 12 Gy RT was given to both lungs. Tamoxifen, anastrozole and letrozole were started 1 week before the RT and continued until the animals were sacrificed 16 weeks after the RT. As an end point, the extent of pulmonary fibrosis for each rat was quantified with image analysis of histological sections of the lung. Kruskal-Wallis and Mann-Whitney U tests were used for statistical analyses.
RESULTS: The congestion, inflammation and pulmonary fibrosis scores were significantly different between all the study groups (p values were <0.001 for each). When compared with RT only group, concomitant RT and tamoxifen group increased the radiation-induced pulmonary fibrosis (p = 0.005). However, using either anastrozole or letrozole with RT did not increase the radiation-induced pulmonary fibrosis (p values were 0.768 and 0.752, respectively).
CONCLUSION: Concomitant use of tamoxifen with RT seems to increase radiation-induced pulmonary toxicity. However, the use of both anastrozole and letrozole appears to be safe with concomitant RT, without increasing the risk of pulmonary fibrosis. This finding should be clarified with further clinical studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941118     DOI: 10.1007/s00520-012-1584-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  30 in total

1.  Target cells in radiation pneumopathy.

Authors:  Klaus Rüdiger Trott; Thomas Herrmann; Michael Kasper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

Review 2.  Selective estrogen receptor modulation: concept and consequences in cancer.

Authors:  V Craig Jordan
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

Review 3.  Radiation pulmonary toxicity: from mechanisms to management.

Authors:  Paul R Graves; Farzan Siddiqui; Mitchell S Anscher; Benjamin Movsas
Journal:  Semin Radiat Oncol       Date:  2010-07       Impact factor: 5.934

4.  Challenges in defining radiation pneumonitis in patients with lung cancer.

Authors:  Zafer Kocak; Elizabeth S Evans; Su-Min Zhou; Keith L Miller; Rodney J Folz; Timothy D Shafman; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

5.  Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen.

Authors:  D E Wazer; O F Tercilla; P S Lin; R Schmidt-Ullrich
Journal:  Br J Radiol       Date:  1989-12       Impact factor: 3.039

6.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

Authors:  A Buzdar; A Howell; J Cuzick; C Wale; W Distler; G Hoctin-Boes; J Houghton; G Y Locker; J M Nabholtz
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

7.  Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro.

Authors:  G H Paulsen; T Strickert; A B Marthinsen; S Lundgren
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

8.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

9.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Authors:  John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

10.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

View more
  8 in total

1.  Blocking HMGB1 signal pathway protects early radiation-induced lung injury.

Authors:  Liping Wang; Jing Zhang; Baozhong Wang; Guifu Wang; Junlong Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.

Authors:  Yuan Zhuang; Sihan Li; Huihui Wang; Jingbo Pi; Yuhui Xing; Guang Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

Review 3.  Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.

Authors:  Matthew J Cecchini; Edward Yu; Kylea Potvin; David D'souza; Michael Lock
Journal:  Cureus       Date:  2015-10-25

4.  Changes in lung volume parameters regarding the received dose in the lobes of the lungs after locoregional radiotherapy of breast cancer.

Authors:  Mahsa Abdemanafi; Mohammad Bagher Tavakoli; Ali Akhavan; Iraj Abedi
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-16

5.  A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy.

Authors:  Matthew J Cecchini; Edward Yu; Brian P Yaremko; R Gabriel Boldt; Kylea Potvin; Tracy Sexton; David D'Souza; Muriel Brackstone; Michael Lock
Journal:  Cureus       Date:  2016-04-03

6.  Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial.

Authors:  Céline Bourgier; Florence Castan; Olivier Riou; Tan-Dat Nguyen; Karine Peignaux; Claire Lemanski; Jean-Léon Lagrange; Youlia Kirova; Eric Lartigau; Yazid Belkacemi; Sofia Rivera; Georges Noël; Sébastien Clippe; Françoise Mornex; Christophe Hennequin; Sophie Gourgou; Muriel Brengues; Pascal Fenoglietto; Esat Mahmut Ozsahin; David Azria
Journal:  Oncotarget       Date:  2018-03-02

7.  Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice.

Authors:  Xiaoman Li; Dehui Ma; Xiaodan Zha; Dongqin Quan; Dong Pan; Manji Sun; Burong Hu; Baoquan Zhao
Journal:  Oncotarget       Date:  2017-06-15

Review 8.  Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management.

Authors:  Arnaud Beddok; Paul Cottu; Alain Fourquet; Youlia Kirova
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.